Our results suggest that G0S2 could serve as an important biomarker for predicting the efficacy of PD-1 inhibitors in HCC patients and provide a theoretical basis for developing combination therapy strategies targeting G0S2. The gene discussed is G0S2; the disease is hepatocellular carcinoma.